Last reviewed · How we verify
Vaccin GenHevac B Pasteur
GenHevac B Pasteur is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.
GenHevac B Pasteur is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B infection in infants, children, and adults.
At a glance
| Generic name | Vaccin GenHevac B Pasteur |
|---|---|
| Sponsor | Central Hospital, Nancy, France |
| Drug class | Recombinant hepatitis B vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains hepatitis B surface antigen produced through recombinant DNA technology. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (anti-HBs) and memory B cells. This immunological memory enables rapid immune response upon exposure to the actual hepatitis B virus, preventing infection and disease development.
Approved indications
- Prevention of hepatitis B infection in infants, children, and adults
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Low Grade Lymphoma (PHASE4)
- Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST) (PHASE3)
- Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |